These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 27750195

  • 1. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
    Guillaume YC, Lethier L, André C.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov 15; 1036-1037():142-148. PubMed ID: 27750195
    [Abstract] [Full Text] [Related]

  • 2. Comparative binding to DR4 and DR5 receptors of TRAIL and BNNTs/PAHE/mPEG-DSPE/TRAIL nanoparticles.
    Guillaume YC, André C.
    J Mol Recognit; 2017 Jul 15; 30(7):. PubMed ID: 28120533
    [Abstract] [Full Text] [Related]

  • 3. Enhanced DR5 binding capacity of nanovectorized TRAIL compared to its cytotoxic version by affinity chromatography and molecular docking studies.
    Zakaria A, Picaud F, Guillaume YC, Gharbi T, Micheau O, Herlem G.
    J Mol Recognit; 2016 Sep 15; 29(9):406-14. PubMed ID: 26952193
    [Abstract] [Full Text] [Related]

  • 4. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
    Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A, Serrano L, Quax WJ.
    J Biol Chem; 2008 Jul 18; 283(29):20560-8. PubMed ID: 18474604
    [Abstract] [Full Text] [Related]

  • 5. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.
    Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML.
    J Biol Chem; 2000 Jul 28; 275(30):23319-25. PubMed ID: 10770955
    [Abstract] [Full Text] [Related]

  • 6. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S.
    Int J Radiat Oncol Biol Phys; 2008 Oct 01; 72(2):543-52. PubMed ID: 18793956
    [Abstract] [Full Text] [Related]

  • 7. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J, Li G, Zhang K.
    Biomed Pharmacother; 2016 Dec 01; 84():1078-1087. PubMed ID: 27780136
    [Abstract] [Full Text] [Related]

  • 8. The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex.
    Ramamurthy V, Yamniuk AP, Lawrence EJ, Yong W, Schneeweis LA, Cheng L, Murdock M, Corbett MJ, Doyle ML, Sheriff S.
    Acta Crystallogr F Struct Biol Commun; 2015 Oct 01; 71(Pt 10):1273-81. PubMed ID: 26457518
    [Abstract] [Full Text] [Related]

  • 9. The enhanced expression of death receptor 5 (DR5) mediated by HBV X protein through NF-kappaB pathway is associated with cell apoptosis induced by (TNF-α related apoptosis inducing ligand) TRAIL in hepatoma cells.
    Kong F, You H, Zhao J, Liu W, Hu L, Luo W, Hu W, Tang R, Zheng K.
    Virol J; 2015 Nov 17; 12():192. PubMed ID: 26577955
    [Abstract] [Full Text] [Related]

  • 10. Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing.
    Zakaria AB, Picaud F, Rattier T, Pudlo M, Dufour F, Saviot L, Chassagnon R, Lherminier J, Gharbi T, Micheau O, Herlem G.
    Nano Lett; 2015 Feb 11; 15(2):891-5. PubMed ID: 25584433
    [Abstract] [Full Text] [Related]

  • 11. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
    Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva AM, Moshkovskii SA, Kirpichnikov MP.
    Apoptosis; 2009 Jun 11; 14(6):778-87. PubMed ID: 19412666
    [Abstract] [Full Text] [Related]

  • 12. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 13. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
    Jalving M, Heijink DM, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J, Sluiter WJ, de Vries EG, Kleibeuker JH, de Jong S.
    Carcinogenesis; 2014 May 15; 35(5):1092-9. PubMed ID: 24379239
    [Abstract] [Full Text] [Related]

  • 14. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B, van Roosmalen IAM, Reis CR, Setroikromo R, Quax WJ.
    FEBS J; 2019 Feb 15; 286(3):555-571. PubMed ID: 30589515
    [Abstract] [Full Text] [Related]

  • 15. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME, Bychkov ML, Yagolovich AV, Dolgikh DA, Kirpichnikov MP.
    Biochemistry (Mosc); 2015 Aug 15; 80(8):1080-91. PubMed ID: 26547077
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.
    Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, Samali A, Serrano L, Quax WJ.
    Biochemistry; 2009 Mar 17; 48(10):2180-91. PubMed ID: 19236007
    [Abstract] [Full Text] [Related]

  • 17. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Röder C, Schütze S, Wajant H, Kalthoff H, Trauzold A.
    J Mol Med (Berl); 2010 Jul 17; 88(7):729-40. PubMed ID: 20354842
    [Abstract] [Full Text] [Related]

  • 18. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y, Zhang B.
    Mol Cancer Res; 2008 Dec 17; 6(12):1861-71. PubMed ID: 19074831
    [Abstract] [Full Text] [Related]

  • 19. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
    Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S, Zacharias W.
    BMC Cancer; 2007 Jun 25; 7():108. PubMed ID: 17592646
    [Abstract] [Full Text] [Related]

  • 20. DR4-Ser424 O-GlcNAcylation Promotes Sensitization of TRAIL-Tolerant Persisters and TRAIL-Resistant Cancer Cells to Death.
    Lee H, Oh Y, Jeon YJ, Lee SY, Kim H, Lee HJ, Jung YK.
    Cancer Res; 2019 Jun 01; 79(11):2839-2852. PubMed ID: 30987996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.